IP Library Granted Patent US 7,795,390
Granted Patent B2
US 7,795,390 · App. 11/474,282 · Granted Sep 14, 2010

Biological substance nesfatin and its related substances and uses thereof

Assignees: Teijin Pharma Limited; National University Corporation Gunma University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,795,390
App. No.
11/474,282
Granted
Sep 14, 2010
Kind
B2
Abstract

The present invention relates to a novel method of obtaining a factor involved in appetite control and/or body weight control, as well as genes obtained by said method, polypeptides encoded by said genes, or novel polypeptides obtained from the information on polypeptides encoded by said genes as a means for treating, controlling or diagnosing diseases associated with eating disorders and/or body weight control. Also the present invention relates to substances that inhibit the effects of said genes or said polypeptides as a means for treating, controlling or diagnosing diseases associated with appetite control and/or body weight control. By using thiazolidine diones having a PPAR γ agonist activity, genes and polypeptides involved in appetite regulation and/or body weight reduction can be obtained. NESFATIN or the like obtained by said method can be used as a means for treating, controlling or diagnosing diseases associated with eating disorders and/or body weight control.

Claims (7)

1. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:13, or a fragment thereof having an activity of suppressing food intake or suppressing body weight gain.

2. An isolated polypeptide having an activity of suppressing food intake or suppressing body weight gain, wherein said polypeptide consists of an amino acid sequence at least 80% identical to SEQ ID NO: 13.

3. A pharmaceutical composition comprising the polypeptide according to claim 1 or 2 , and a pharmaceutically acceptable carrier.

4. An isolated polypeptide having an activity of suppressing food intake or suppressing body weight gain, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 13, with the proviso that said polypeptide is not NUCB2.

5. An isolated polypeptide having an activity of suppressing food intake or suppressing body weight gain, wherein said polypeptide comprises an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 13, with the proviso that said polypeptide is not NUCB2.

6. An isolated polypeptide having an activity of suppressing food intake or suppressing body weight gain, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 13, and wherein said polypeptide does not contain a prohormone convertase cleavage site.

7. An isolated polypeptide having an activity of suppressing food intake or suppressing body weight gain, wherein said polypeptide comprises an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 13, and wherein said polypeptide does not contain a prohormone convertase cleavage site.

Assignments (3)
CHANGE OF ADDRESS Recorded Jan 18, 2013
From: TEIJIN PHARMA LIMITED
To: TEIJIN PHARMA LIMITED
Reel/Frame 029660/0419 →
COPORATE SPLIT Recorded Jan 18, 2013
From: TEIJIN PHARMA LIMITED
To: TEIJIN LIMITED
Reel/Frame 029660/0489 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2006
From: MORI, MASATOMO; SHIMIZU, HIROYUKI; EGUCHI, HIROSHI; YAMAMOTO, MASANORI
To: TEIJIN PHARMA LIMITED; NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
Reel/Frame 018733/0702 →
Priority Claims (1)
JP 2005-184441 · Jun 24, 2005 · national
Continuity (3)
Provisional Application 6070386400 · Aug 1, 2005
Provisional Application 6078051400 · Mar 9, 2006
Related Publication 20080115231A1 · May 15, 2008